“A great opportunity to meet FDA colleagues and interact with experts in different fields.”
- Bioanalytical Principal Investigator, Senior Scientist, Pfizer

“The Summit was a fantastic meeting. It was an exciting opportunity to connect with colleagues and collaborators and to discuss the cutting-edge developments in protein drug immunogenicity.”
- Assistant Professor, The University of Kansas

“Extremely high-quality presentations and excellent networking opportunities. Feedback from the FDA was invaluable”
- Professor, Head and Member, La Jolla Institute for Immunology

“I learned a lot about bioanalytical challenges and needs on novel modalities, which ultimately translates into faster drug products delivered to those that need them.”
- Bioanalytical Principal Investigator, Senior Scientist, Pfizer

“The Immunogenicity & Bioassay Summit was a real success. It was a very nice opportunity to meet talented scientists in the field.”
- Research Director, Immunology, CEA

"I highly recommend this class for any analyst that needs to know whether a result can be accepted or rejected with confidence, or if suitable for the intended use. Nancy Sajjadi has put together a concise, well-presented course. Prepare to be challenged! The open forum small class is conducive to discuss common methodologies, regulatory guidelines, and analytical method validation. A great class as a refresher or to learn something new."
- Research and Development Manager, Assay Development, AGTC

"I think your conference is one of the best ones focused on immunogenicity. Your ability to attract multiple FDA speakers is a big plus."
- CSO, Selecta Biosciences

I think this is one of the best meetings in the field for immunogenicity and appreciate that experts in the field from industry, academia, and regulatory are brought together into one small forum. The talks and breakout sessions were very informative.
- Principal Scientist,Process Development, Amgen, Inc.

The immmunogenicity summit is one of the highlights of the year for me.
- Biotech Quality and Immunogenicity Reviewer, Biotechnology Products, CDER-FDA

This event has a great atmosphere for networking and learning about new expectations in our always changing field.
- Senior Group Leader, Immunogenicity PPD, Inc.

Allows open discussion with colleagues from other companies and with regulators.
- Associate Director, Biomarkers and Clinical Bioanalysis, Translational Medicine and Early Development, Sanofi

High quality speakers and interesting topics.
- Director and Head, Project Support for New Biological Entities, Quantitative Pharmacology and Drug Disposition, EMD Serono

Always an excellent meeting for measuring the pulse of the industry and gaining insight about trends and challenges from thought leaders and regulators alike.
- Research Scientist, Immunology, Charles River Labs Preclinical Services, Montreal Inc.

Very good interaction and Q&A between participants; Informal interactions which allow the sharing of more information than can be raised in a talk.
- Senior Director, Immunogenicity Assessment, Biomarin Pharmaceutical Inc.

"I really enjoyed the conference. There were quite a few FDA attendees that made themselves available for informal conversations and interactions. In general, there seemed to be a good balance between formal presentations and informal interactions."
- Senior Director, Immunogenicity Assessment, Biomarin Pharmaceutical Inc.

Thank you for wonderful sessions.
- Medicinal Safety Research, Daiichi-Sankyo

Has the right people with the right talks which promotes constructive conversations and perhaps future collaborations.
- Post-Doctoral Fellow, Molecular Biology, National Cancer Institute

I really liked the wide and deep background provided by the highly specialized speakers. Everyone in the field should attend this class.
- Post-Doctoral Fellow, Molecular Biology, National Cancer Institute

This is the highlight of this conference: wonderful talks.
- Group Leader, R&D, Promega

It was a very interesting meeting with an excellent level.
- Head, R&D, UDIBI IPN

Great workshop; good coverage of the background info, also lots of case studies and examples from the clinic.
- Scientist, Contract Assay Services, Stem Cell Technologies

It was great to have the opportunity to talk at the CHI meeting. I thought the meeting was really well attended and also had a great range on speakers on key topics.
- Staff Scientist, BioAnalytical Sciences, Genentech, Inc.

As always, it was a fantastic event with respect to both the content and the networking opportunities.
- Associate Professor, Thayer School of Engineering, Dartmouth

High quality content in different assay formats and technologies for immunogenicity assessment."
- Senior Research Associate, Bioanalytical, Cliantha Research Ltd.

Interesting new data; very relevant to the field."
- Senior Scientist, Process Development, Amgen, Inc.

"The topics discussed were important, and the speakers were excellent".
- Senior Director, Non-clinical Development, Versatis